Esperion Therapeutics Inc (ESPR) — Who's Buying and Selling (13F, Q2 2026)

ESPR ranks #3051 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

ESPR is a top-conviction position for Trium Capital LLP — at 21.7% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in ESPR belongs to BlackRock, Inc., but the position matters far more to Trium Capital LLP, who has 21.7% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Fidelity has added to its ESPR position for two straight quarters, increasing it by $14.3M to reach $14.6M today.

Marshall Wace, LLP has trimmed its ESPR position for two straight quarters, cutting it by $20.2M while still holding $44.6K.

ESPR reported a net loss of $7.4M over the trailing twelve months.

• Not yet profitable — net loss of $7.4M over the trailing twelve months
• Revenue grew 61.1% year over year
• Net income improved year over year, from -$153.2M to -$7.4M
• Operating cash flow was negative, using $13.1M in cash
• Current ratio of 1.54x — enough short-term assets to cover short-term liabilities